Agreement reached between SpectraCure and one more hospital – Memorial Sloan Kettering Cancer Center i n New York
SpectraCure AB (publ) and Memorial Sloan Kettering Cancer Center in New York, USA, have today signed an agreement, which means that the hospital will be the fourth hospital in SpectraCure's clinical program. A formal meeting ("Site Initiation Visit") for the start-up and review of routines and equipment will be arranged between the company and the […]
Year End Report 2019
Fourth quarter (1 October – 31 December 2019) Other income amounted to TSEK 1 243 (TSEK 197). Profit after tax amounted to TSEK -3 706 (-3 242). Corresponding to SEK -0,04 (-0,05) per share before and after diluted earnings. Operating cash flow was TSEK -3 407 (-3 806). Full year 2019 Other income amounted to TSEK 3 248 (1 […]
Reinforcements in SpectraCure’s organization
Today we are welcoming Johan Glindre to SpectraCure. Johan Glindre will be working as a Clinical Project Leader and has a solid background in clinical studies, project management and quality work. Johan holds a Master of Molecular Biology from Lund University, and has among other things, been working for Pharmacia and OctaPharma with quality work […]
A welcome addition to support our ongoing product development. SpectraCure receives research contribution from the EU.
SpectraCure (http://www.SpectraCure.com)has been awarded with funds from the EU which strengthens the research within the company’s technology, to treat prostate cancer with SpectraCure’s IDOSE dose platform and focal PDT treatment (PDT). The funding enables the employment of a young researcher for four years. The funding is part of an Innovative Training Network where SpectraCure participates […]
Exercise rate of 98.8 percent for SpectraCure’s warrants (TO3)
On 29 November, SpectraCure AB (publ) (“SpectraCure”) ended the exercise period for the Series 3 TO3 B subscription warrants. In total, 5,828,739 shares have been subscribed during the now concluded exercise period. SpectraCure is thus provided MSEK 37.9 in proceeds, before issuance costs to the estimated amount of MSEK 1.1. The exercise rate was 98.8 percent. As […]
Last day of trading of SPEC TO3 subscription warrants tomorrow, Nov. 27
The last day of trading of SpectraCure AB (publ) TO3 is Wednesday, November 27th, 2019. Subscription of shares supported by the warrants in the TO3 program, implies that every two (2) warrants entitles the holder to subscribe for one (1) new share in SpectraCure at the subscription price of SEK 6.50. If all warrants are fully […]
SpectraCure´s main owner subscribes in full for his share
SpectraCure's main owner and CEO Masoud Khayyami subscribes in full through his company Cardeon Futuring Finance his share in the company's warrants program TO3, corresponding to 1 653 382 warrants. Cardeon Futuring Finance's total holding in SpectraCure after the issue amounts to 2 480 073 shares. Prior to the acquisition Masoud Khayyami, privately and with companies […]
SpectraCure AB Quarterly Report (1 July to 30 September) 2019
Third quarter (1 July – 30 September 2019) Other income amounted to TSEK 692 (215). Profit after tax amounted to TSEK -3 054 (-1 922). Corresponding to SEK -0,04 (-0,03) kr per share before and after diluted earnings. Operating cash flow was TSEK -3 072 (-2 640). Cash as of 30 September amounted to TSEK 25 421 (2 185) TSEK. Equity ratio: 81 […]
The FDA’s initiative can provide faster market access for SpectraCure
During SpectraCure's ongoing clinical trial, the American FDA (Food and Drug Administration) has created an opening for faster product launch by changing the requirements for endpoints in clinical trials in cancer treatment. The changed requirements provide new opportunities that in the long term may entail faster market access. The FDA's initiative to admit shorter […]
SpectraCure at Stora Aktiedagen in Gothenburg
A new opportunity to listen to Masoud Khayyami, CEO of SpectraCure, will be at Stora Aktiedagen in Gothenburg November 4th. The SpectraCure Company presentation, including the status of current clinical study, will be held at 1.30 p m. The event will be streamed at www.aktiespararna.se/tv/live. Where: Hall G3, Svenska Mässan, Mässans Gata 24, Gothenburg For further information, contact: SpectraCure […]
